Laboratory for Advanced Medicine to Present at 2018 Biotech Showcase

IRVINE, Calif., Jan. 3, 2018 /PRNewswire/ -- Laboratory for Advanced Medicine (LAM), a clinical-stage biopharmaceutical company focused on developing cutting-edge non-invasive, non-toxic technologies for early diagnosis and intervention of various cancers, today announced that the Company's founder and chairman, Shu Li, will present at the 10th Annual Biotech Showcase™, taking place on Jan. 8 through 10, 2018, in San Francisco, Calif.

Dr. Li will present an overview of LAM's business, technology and strategic growth objectives and will also be available to participate in one-on-one meetings with members of the financial and financial media communities. The details of his presentation are as follows:

Date: Tuesday, Jan. 9, 2018
Time: 3:00 p.m. PST (6:00 p.m. EST)
Location: Franciscan - D (Ballroom level), Hilton San Francisco Union Square (333 O'Farrell St., San Francisco, Calif., 94102)

The largest international biotech investor conference in the world, Biotech Showcase brings together life sciences decision-makers and investors from across the globe to collaborate and discuss industry trends through panels, workshops and fireside chats. Additional information and registration can be found here: https://ebdgroup.knect365.com/biotech-showcase/.

To schedule a meeting with Dr. Li during the Biotech Showcase, contact [email protected].

About Laboratory for Advanced Medicine
LAM is a clinical-stage biopharmaceutical company focused on developing cutting-edge non-invasive, non-toxic technologies for early diagnosis and intervention, possibly years before symptoms arise. LAM is dedicated to building and growing world-class technologies still in development from the laboratory to the clinic. LAM operates scientifically, ethically and efficiently to bring these cutting-edge technologies into the mainstream.

LAM is headquartered in the United States with offices in California, Texas and Indiana. LAM is a multinational business with collaborations in both the United States and China, including leading scientists, physicians, research institutions and business leaders. LAM strives to combine the experiences of these innovators and achievers to provide the healthiest and safest diagnostic technologies to everyone.

LAM has CLIA- and CAP-certified laboratories, third-party laboratories and cGMP facilities all working toward the endeavor of bringing these first-class technologies into the medical community.

About IvyGene®
The IvyGene test is owned by the Laboratory for Advanced Medicine, Inc. IvyGene is a blood test for the presence of cancer and quantification of ctDNA presence. IvyGene leverages studies using advanced DNA sequencing methods to detect the DNA methylation pattern of cell-free DNA in blood. The sequence, along with the pattern of methylated DNA, is consistent with cancer presence.

Unlike many genetic tests that use DNA to determine the propensity or possibility of developing cancer over time, the IvyGene test identifies DNA methylation patterns consistent with actual disease presence and quantification of ctDNA presence at the time of testing.

SOURCE Laboratory for Advanced Medicine

Related Links

https://www.lamoncogroup.com